Cancer - Prostate(구연) (E-102) 전립선암 환자에서 남성호르몬 박탈요법과 치매의 연관성 연세의대 강남세브란스병원 비뇨의학과, ¹순천향의대 순천향대학교병원 비뇨의학과, ²연세의대 의생명시스템정보학교실 김종원, 김도경¹, 이혜선², 박주영², 하지수, 이돈구, 안현규, 조강수 There has been the controversy about the effect of androgen deprivation therapy (ADT) on the occurrence of dementia. We performed a nationwide population-based cohort study to investigate the risk of dementia associated with ADT in men with prostate cancer. A total of 218,203 men with prostate cancer were identified between 2008 and 2017 from the nationwide claims database in Korea. A total of 132,700 patients fitted inclusion and exclusion criteria were included for the analysis. For the adjustment comorbidities between the cohorts, 1:1 exact matching was used. Kaplan-Meier survival analysis was used to estimate cumulative incidence of dementia. Cox proportional hazard regression models was used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of events associated with ADT. After 1:1 exact matching, a total of 44,854 men with prostate cancer were selected for main analysis. Univariable analysis revealed that ADT group had higher cumulative incidence of overall dementia (log-rank p = 0.0007) and Alzheimer’s dementia (log-rank p = 0.0006) than non-ADT group. However, there was no difference in cumulative incidence of vascular dementia according to use of ADT (log-rank p = 0.7473) (Fig. 1). In multivariable Cox regression analysis, ADT group was also significantly associated with an increased risk of overall dementia (HR, 1.091; 95% CIs, 1.029-1.157; p = 0.0033) and Alzheimer’s dementia (HR, 1.110; 95% CIs 1.040 – 1.185, p = 0.0017) compared to non-ADT group. However, there was no difference in vascular dementia between ADT and non-ADT groups (HR, 1.091; 95% Cis, 1.029-1.157; p = 0.9406). In conclusion, the risk of overall dementia increased in men who underwent ADT. According to subtypes of dementia, ADT was associated with an increased risk of Alzheimer’s dementia, but not with vascular dementia. keywords : Androgen deprivation therapy, Dementia, Prostate cancer